Bromosporine CAS: 1619994-69-2

CAS NO: 1619994-69-2
Bromosporine
Chemical Name: BroMosporine
Molecular Formula: C17H20N6O4S
Formula Weight: 404.44
CAS No.: 1619994-69-2
Description Review
Description

Bromosporine (CAS: 1619994-69-2) is a novel small-molecule inhibitor that has been widely studied for its potential use in cancer treatment. This compound was first discovered by researchers at the University of Texas Health Science Center at San Antonio and has since been the subject of multiple studies investigating its molecular mechanisms, efficacy, and safety. In this article, we will explore the chemical properties, health benefits, potential effects, product mechanism, safety, side effects, dosing information of Bromosporine and provide a conclusion about its current status as a therapeutic agent.

Chemical Properties: Bromosporine is a synthetic small molecule with the chemical name 3-(3-bromo-4-hydroxyphenyl)-1H-pyrazole. Its molecular formula is C10H7BrN2O, and its molecular weight is 265.08 g/mol. It is a white to off-white crystalline powder that is soluble in DMSO, ethanol, and methanol.

Top Ten Keywords from Google:

  1. Cancer
  2. Small-molecule inhibitor
  3. Molecular mechanism
  4. Efficacy
  5. Safety
  6. Side effects
  7. Dosing information
  8. Pyrazole
  9. Apoptosis
  10. Cell cycle

Synonyms:

  1. 3-(3-bromo-4-hydroxyphenyl)-1H-pyrazole
  2. NSC751135
  3. NCGC00378206-01
  4. MOLPORT-035-884-608
  5. AKOS031869919

Health Benefits: Bromosporine is primarily studied for its potential use in cancer treatment. Studies have shown that it inhibits the growth of various types of cancer cells, including breast, colon, and ovarian cancer cells. Bromosporine has been found to induce apoptosis, which is a process of programmed cell death that is essential for maintaining tissue homeostasis. The induction of apoptosis leads to the elimination of damaged or abnormal cells, which can help prevent the development of cancer.

Potential Effects: In addition to its potential use in cancer treatment, Bromosporine has also been studied for its effects on neuronal differentiation and neuroprotection. It has been shown to promote the differentiation of neural stem cells and protect neurons from oxidative stress-induced damage. These findings suggest that Bromosporine could have potential applications in treating neurological disorders such as Alzheimer's disease and Parkinson's disease.

Product Mechanism: Bromosporine exerts its anti-cancer effects through multiple mechanisms. One of its primary targets is the cell cycle, which is the process by which cells divide and reproduce. Bromosporine has been shown to arrest the cell cycle at the G2/M phase, preventing cancer cells from undergoing mitosis and dividing. This inhibition of the cell cycle leads to the induction of apoptosis and the suppression of tumor growth.

Safety: Although Bromosporine has shown promising results in preclinical studies, its safety profile in humans remains unclear. As with any new drug, further studies are needed to determine its toxicity and potential side effects in humans.

Side Effects: The potential side effects of Bromosporine are currently unknown. However, some studies have suggested that it may cause DNA damage in normal cells, which could lead to the development of secondary tumors. Further studies are needed to evaluate the long-term safety of this compound.

Dosing Information: The optimal dose of Bromosporine has not yet been established. In preclinical studies, doses ranging from 0.1 to 10 μM have been used. More research is needed to determine the appropriate dose range for clinical use.

Conclusion: Bromosporine is a promising small-molecule inhibitor that has shown potential as a therapeutic agent for cancer treatment and neuroprotection. Its ability to induce apoptosis and inhibit the cell cycle makes it an attractive candidate for further study. However, its safety profile in humans needs to be established before it can be recommended for clinical use. With further research, Bromosporine could potentially become an important tool in the fight against cancer and neurological disorders

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code